Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.4145
- Book/Share 19.5994
- PB 4.2881
- Debt/Equity 0.7226
- CurrentRatio 1.4236
- ROIC 0.1828
- MktCap 209638944899.0
- FreeCF/Share 5.8814
- PFCF 14.2398
- PE 12.8056
- Debt/Assets 0.3012
- DivYield 0.0386
- ROE 0.3488
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.
Read More
Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
Merck earns a "Strong Buy" rating due to strategic moves, including FDA approval of QLEX, the first subcutaneous immune checkpoint inhibitor. QLEX extends Keytruda's patent life, offering rapid, flexible dosing and broader treatment settings, countering the upcoming IV Keytruda patent cliff in 2028. MRK's acquisition of Verona Pharma adds Ohtuvayre for COPD, expanding its cardiopulmonary portfolio and future growth opportunities.
Read More
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worseni.
Read More
Big Pharma braces for the next price cut
Published: September 26, 2025 by: Proactive Investors
Sentiment: Negative
Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.
Read More
Merck: Game-Changing Oncology Drugs Power Stock Surge
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Positive
Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-on-quarter, thanks in part to its label expansion on May 14. Strong performance from two cardiovascular 'stars,' Winrevair and Adempas, led Merck to buy back about $1.35 billion in shares in Q2 2025, more than quadrupling year-on-year.
Read More
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Read More
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
Published: September 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they offer a significant income stream and have massive total return potential.
Read More
Merck: 25% Total Return CAGR Potential
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like Verona Pharma, is expected to offset patent expirations and drive future revenue. Dividend growth is projected at 6.5% CAGR, supported by a strong balance sheet, high profitability, and superior free cash flow versus peers.
Read More
Here's Why Merck (MRK) is a Strong Value Stock
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape
Published: September 24, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new vaccine landscape, demand for Merck's vaccines, future of drug pricing, and more.
Read More
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
Read More
US FDA approves Merck's new injectable version of Keytruda
Published: September 19, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient option of the widely used cancer immunotherapy, the health regulator said on Friday.
Read More
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
Read More
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Read More
Rate Cuts Could Actually Spark a Sell-Off: 5 Safe JP Morgan Dividend Stocks
Published: September 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Markets often rally in anticipation of rate cuts but then decline when the actual rate cuts are implemented.
Read More
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the.
Read More
Merck: Buy This Dividend Powerhouse While It's Cheap
Published: September 16, 2025 by: Seeking Alpha
Sentiment: Positive
Merck offers a compelling opportunity for long-term income and value investors, trading near its 52-week low with a 4% dividend yield. MRK's robust drug pipeline, strong balance sheet, and strategic acquisitions like Verona Pharma support future growth despite near-term GARDASIL challenges in China. Keytruda's ongoing expansion, new launches like WINREVAIR, and over 80 Phase III studies underpin MRK's growth potential and sector-leading profitability.
Read More
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.
Read More
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Read More
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
Read More
Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:50 AM EDT Company Participants Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Caroline Litchfield - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today for the lunch session. My name is Mohit Bansal.
Read More
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Read More
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Read More
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Read More
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Read More
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
Read More
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Published: August 27, 2025 by: Benzinga
Sentiment: Positive
Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.
Read More
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
Published: August 27, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000